On December 17, 2018, Rajen Dalal submitted his resignation as a director from the Board of Directors of the Soleno Therapeutics, Inc., as well as from the Audit Committee of the Board of Directors and the Nominating and Corporate Governance Committee of the Board of Directors effective January 1, 2019. On December 17, 2018, the Board appointed Andrew Sinclair, Ph.D. to the Board, effective upon the closing of the Private Placement. Dr. Sinclair will serve as a Class I director, with a term expiring at the annual meeting of stockholders to be held in 2021, when he is expected to stand for election by a vote of the Company’s stockholders. Dr. Sinclair will also serve on the Audit Committee and the Nominating Committee. Since 2008, Dr. Sinclair has held various positions at Abingworth LLP, where he is currently a Partner and Portfolio Manager.
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCRâs mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.
SOLENO THERAPEUTICS, INC. 
